Insider Selling: Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Insider Sells 10,000 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 25th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the transaction, the insider now owns 122,279 shares in the company, valued at $1,694,786.94. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Centessa Pharmaceuticals Stock Down 5.4%

CNTA stock opened at $13.43 on Thursday. The stock has a market capitalization of $1.79 billion, a P/E ratio of -7.42 and a beta of 1.48. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $8.46 and a 12 month high of $19.09. The firm has a 50-day moving average price of $12.79 and a 200-day moving average price of $14.78.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.15. As a group, equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CNTA shares. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued a “buy” rating and a $30.00 price target on the stock. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price target on the stock. Morgan Stanley restated an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.89.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CNTA. JPMorgan Chase & Co. raised its holdings in Centessa Pharmaceuticals by 40.1% in the 4th quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company’s stock valued at $3,189,000 after buying an additional 54,482 shares during the last quarter. Wellington Management Group LLP raised its holdings in Centessa Pharmaceuticals by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock valued at $1,928,000 after buying an additional 14,494 shares during the last quarter. Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock valued at $38,668,000 after buying an additional 6,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after buying an additional 660 shares during the last quarter. Finally, Trexquant Investment LP increased its position in Centessa Pharmaceuticals by 52.8% during the 4th quarter. Trexquant Investment LP now owns 261,184 shares of the company’s stock valued at $4,375,000 after purchasing an additional 90,233 shares during the period. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.